诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688428 诺诚健华

交易中 07-18 14:39:56

{"stockData":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":9.38,"timestamp":1721284796000,"preClose":9.35,"halted":0,"volume":4064159,"delay":0,"floatShares":258000000,"shares":1764000000,"eps":-0.4316,"marketStatus":"交易中","marketStatusCode":2,"change":0.03,"latestTime":"07-18 14:39:56","open":9.11,"high":9.41,"low":9.08,"amount":37481300,"amplitude":0.0353,"askPrice":9.39,"askSize":22,"bidPrice":9.38,"bidSize":93,"shortable":0,"etf":0,"ttmEps":-0.4316,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1721286000000},"adr":0,"adjPreClose":9.35,"symbolType":"stock_kcb","openAndCloseTimeList":[[1721266200000,1721273400000],[1721278800000,1721286000000]],"highLimit":10.29,"lowLimit":8.42,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1764217202,"pbRate":2.35,"roa":"--","roe":"--","epsLYR":-0.37,"committee":-0.478321,"marketValue":16548000000,"floatMarketCap":2423000000,"peRate":-21.733086,"changeRate":0.0032,"turnoverRate":0.0157,"status":0},"requestUrl":"/m/hq/s/688428","defaultTab":"news","newsList":[{"id":"2452814939","title":"诺诚健华发布2024年度“提质增效重回报”行动方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2452814939","media":"证券市场周刊","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452814939?lang=zh_cn&edition=full","pubTime":"2024-07-18 10:02","pubTimestamp":1721268149,"startTime":"0","endTime":"0","summary":"奥布替尼在国内已获批3项适应症并均已纳入医保，销售额持续快速增长。此外，诺诚健华不断优化财务管理，提高经营效率；积极提升公司治理水平，提高上市公司质量；提高信息披露质量，加强投资者沟通交流。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071810052595d2694b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071810052595d2694b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688428","09969"],"gpt_icon":0},{"id":"2450829588","title":"诺诚健华(09969)：163.475万股A股将于7月18日上市流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2450829588","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450829588?lang=zh_cn&edition=full","pubTime":"2024-07-12 18:42","pubTimestamp":1720780923,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华(09969)发布公告，根据中国证券监督管理委员会、上海证券交易所、中国证券登记结算有限责任公司上海分公司相关规定，该公司于近日收到中国证券登记结算有限责任公司上海分公司出具的《证券变更登记证明》，公司完成了2023年科创板限制性股票激励计划(以下简称“本激励计划”)首次授予部分第一个归属期的股份登记工作。本次A股股票上市流通总数为163.475万股。本次A股股票上市流通日期为2024年7月18日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1150204.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688428","BK1161","BK0239","399300","09969","BK1574","159982"],"gpt_icon":0},{"id":"2450342900","title":"诺诚健华盘中异动 早盘快速上涨5.20%报5.060港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2450342900","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450342900?lang=zh_cn&edition=full","pubTime":"2024-07-12 09:41","pubTimestamp":1720748495,"startTime":"0","endTime":"0","summary":"2024年07月12日早盘09时41分，诺诚健华股票出现波动，股价大幅拉升5.20%。截至发稿，该股报5.060港元/股，成交量67.8万股，换手率0.05%，振幅4.16%。资金方面，该股资金流入202.365万港元，流出92.25万港元。机构评级方面，在所有5家参与评级的机构中，80%的券商给予买入建议，20%的券商给予持有建议，无券商给予卖出建议。诺诚健华股票所在的生物技术行业中，整体涨幅为0.30%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407120941359681c2be&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407120941359681c2be&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688428","09969"],"gpt_icon":0},{"id":"2450870883","title":"诺诚健华-U大幅上涨 获融资净买入173万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2450870883","media":"智选洞察","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450870883?lang=zh_cn&edition=full","pubTime":"2024-07-11 10:15","pubTimestamp":1720664111,"startTime":"0","endTime":"0","summary":"07月11日，诺诚健华-U股价大幅上涨，截至10点15分，诺诚健华-U上涨5.26%，报9.00元/股，成交2053万元，换手率0.91%，振幅5.15%。资金动向截止发稿，诺诚健华-U获得主力净流入38万元，其中超大单流入89万元，大单流出51万元。融资融券方面，诺诚健华-U07月09日获得融资净买入173万元，当日该股融资余额为7123万元，当较前一日增加2.50%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240711101755af91bc36&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240711101755af91bc36&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688428","BK0239"],"gpt_icon":0},{"id":"2449723797","title":"7月8日诺诚健华-U跌6.01%，鹏华医药科技股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2449723797","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449723797?lang=zh_cn&edition=full","pubTime":"2024-07-08 16:12","pubTimestamp":1720426348,"startTime":"0","endTime":"0","summary":"证券之星消息，7月8日诺诚健华-U跌6.01%，收盘报8.45元，换手率2.15%，成交量5.53万手，成交额4783.72万元。重仓诺诚健华-U的公募基金请见下表：该股最近90天内共有4家机构给出评级，买入评级2家，增持评级2家；过去90天内机构目标均价为13.9。根据2024基金Q1季报公募基金重仓股数据，重仓该股的公募基金共7家，其中持有数量最多的公募基金为鹏华医药科技股票A。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070800020166.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","09939","159938","BK1515","BK0239","BK1574","BK1161","688428"],"gpt_icon":0},{"id":"2449743068","title":"诺诚健华-U大跌5.01% 获主力净流入增加","url":"https://stock-news.laohu8.com/highlight/detail?id=2449743068","media":"智选洞察","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449743068?lang=zh_cn&edition=full","pubTime":"2024-07-08 13:36","pubTimestamp":1720416969,"startTime":"0","endTime":"0","summary":"07月08日，诺诚健华-U股价大幅下跌，截至13点36分，诺诚健华-U下跌5.01%，报8.54元/股，成交3164万元，换手率1.41%。资金动向截止发稿，诺诚健华-U获得主力净流出237万元，其中超大单流入106万元，大单流出342万元。最新财报显示，今年一季报，诺诚健华-U实现营业收入1.66亿元，同比减少12.44%，净利润为-1.42亿元，同比减少1047.82%，基本每股收益为-0.08元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240708133644af90fa24&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240708133644af90fa24&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688428","BK0239"],"gpt_icon":0},{"id":"2449712662","title":"诺诚健华(09969)下跌5.26%，报4.68元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2449712662","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449712662?lang=zh_cn&edition=full","pubTime":"2024-07-08 11:46","pubTimestamp":1720410387,"startTime":"0","endTime":"0","summary":"7月8日，诺诚健华(09969)盘中下跌5.26%，截至11:46，报4.68元/股，成交502.35万元。诺诚健华医药有限公司是一家拥有一体化生物医药平台的领先企业，主要从事研发治疗癌症和自身免疫性疾病的创新药物。公司具备强大的内部研发能力和世界级管理团队，同时拥有均衡的管线组合和针对经过验证或新颖生物通路的候选药物。截至2024年一季报，诺诚健华营业总收入1.66亿元、净利润-1.42亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/08114641426609.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","09969","BK1161","BK0239","688428"],"gpt_icon":0},{"id":"2449717555","title":"诺诚健华盘中异动 临近午盘快速下跌5.06%报4.691港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2449717555","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449717555?lang=zh_cn&edition=full","pubTime":"2024-07-08 11:46","pubTimestamp":1720410380,"startTime":"0","endTime":"0","summary":"2024年07月08日临近午盘11时46分，诺诚健华股票出现异动，股价快速跳水5.06%。截至发稿，该股报4.691港元/股，成交量105.1万股，换手率0.07%，振幅5.67%。资金方面，该股资金流入163.997万港元，流出293.1万港元。诺诚健华股票所在的生物技术行业中，整体跌幅为1.44%。诺诚健华公司简介：诺诚健华医药有限公司是一家主要从事生物医药研发、生产和商业化的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407081146209681a7d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407081146209681a7d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09969","688428","BK1574"],"gpt_icon":0},{"id":"2449712015","title":"诺诚健华(09969)股价下跌5.061%，现价港币$4.69","url":"https://stock-news.laohu8.com/highlight/detail?id=2449712015","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449712015?lang=zh_cn&edition=full","pubTime":"2024-07-08 11:46","pubTimestamp":1720410360,"startTime":"0","endTime":"0","summary":"[下跌股]诺诚健华(09969) 股价在上午11:46比前收市价下跌5.061%，现股价为港币$4.69。至目前为止，今日最高价为$4.96，而最低价为$4.69。总成交量为99.2万股，总成交金额为港币$474.622万。","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180416150425748_s.png","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180416150425748_s.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2407081669/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["688428","BK1161","BK1574","BK0239","09969"],"gpt_icon":0},{"id":"2448936804","title":"长城国瑞证券：给予诺诚健华买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2448936804","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448936804?lang=zh_cn&edition=full","pubTime":"2024-07-04 11:57","pubTimestamp":1720065441,"startTime":"0","endTime":"0","summary":"长城国瑞证券有限公司胡晨曦,魏钰琪近期对诺诚健华进行研究并发布了研究报告《血液瘤产品商业化持续推进，自免管线进展可喜》，本报告对诺诚健华给出买入评级，当前股价为9.01元。最新盈利预测明细如下：该股最近90天内共有3家机构给出评级，买入评级1家，增持评级2家；过去90天内机构目标均价为13.9。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070400021847.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","161027","688428"],"gpt_icon":0},{"id":"2448467876","title":"诺诚健华-U(688428)：血液瘤产品商业化持续推进 自免管线进展可喜","url":"https://stock-news.laohu8.com/highlight/detail?id=2448467876","media":"长城国瑞证券有...","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448467876?lang=zh_cn&edition=full","pubTime":"2024-07-04 11:01","pubTimestamp":1720062099,"startTime":"0","endTime":"0","summary":"奥布替尼商业化持续推进，新适应症有望年内提交NDA。除此之外，奥布替尼和ICP-248 联用于1L SLL/SLL 患者的IND 在今年获CDE批准开展。Tafasitamab 联合来那度胺国内BLA 获正式受理，明年有望贡献业绩增量。公司预计2024 年末或2025 年初在中国大陆递交NDA。考虑公司奥布替尼多项血液瘤适应症获批上市、新适应症上市申请在即，销售放量可期；Tafasitamab 上市申请已获受理有望明年开始贡献业绩，自免管线推进顺利，公司总股权价值大于当前市值，我们首次给予其“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024070411014295722e13&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024070411014295722e13&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688428","BK0239"],"gpt_icon":0},{"id":"2448634904","title":"长城国瑞证券给予诺诚健华买入评级，血液瘤产品商业化持续推进，自免管线进展可喜","url":"https://stock-news.laohu8.com/highlight/detail?id=2448634904","media":"每日经济新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448634904?lang=zh_cn&edition=full","pubTime":"2024-07-04 09:16","pubTimestamp":1720055760,"startTime":"0","endTime":"0","summary":"长城国瑞证券07月04日发布研报称，给予诺诚健华（688428.SH，最新价：8.86元）买入评级。评级理由主要包括：1）聚焦恶性肿瘤和自免领域，开发同类最佳或同类首创药物；2）奥布替尼商业化持续推进，新适应症有望年内提交NDA；3）Tafasitamab联合来那度胺国内BLA获正式受理，明年有望贡献业绩增量；4）奥布替尼具有治疗B细胞信号通路异常引起的自身免疫性疾病的潜力；5）NTRK突变为多癌种致病因素，公司研发策略关注儿科人群。风险提示：商业化进度不及预期、研发不及预期，人才流失风险，毛利率下滑风险，医保政策风险。（文章来源：每日经济新闻）","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407040918009571a413&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407040918009571a413&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688428","09969"],"gpt_icon":0},{"id":"2448184971","title":"7月2日诺诚健华-U涨7.32%，鹏华医药科技股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2448184971","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448184971?lang=zh_cn&edition=full","pubTime":"2024-07-02 16:04","pubTimestamp":1719907465,"startTime":"0","endTime":"0","summary":"证券之星消息，7月2日诺诚健华-U涨7.32%，收盘报8.8元，换手率5.67%，成交量14.56万手，成交额1.27亿元。重仓诺诚健华-U的公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级1家，增持评级2家；过去90天内机构目标均价为13.9。根据2024基金Q1季报公募基金重仓股数据，重仓该股的公募基金共7家，其中持有数量最多的公募基金为鹏华医药科技股票A。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070200022755.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","BK1161","BK1574","BK0239","09969","688428","BK1515","159938"],"gpt_icon":0},{"id":"2448275903","title":"【科创板早盘收评】盘面情绪低迷，科创50早盘收跌1.10%，半导体、PCB板块跌幅居前","url":"https://stock-news.laohu8.com/highlight/detail?id=2448275903","media":"犀牛之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448275903?lang=zh_cn&edition=full","pubTime":"2024-07-02 11:40","pubTimestamp":1719891600,"startTime":"0","endTime":"0","summary":"犀牛之星7月2日讯，今日科创板情绪低迷，震荡下探，科创50半日收跌1.10%，报701.80点。截至上午收盘，全市共208只个股收涨，365只个股收跌。涨幅排行方面，诺诚健华-U 涨7.44%居首，芯原股份 涨6.66%次之。跌幅排行方面，大地熊 跌7.94%居首，悦安新材 跌6.91%次之。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407021153399ef19428&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407021153399ef19428&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0256","159982","688786","000688.SH","159582","688428","688077"],"gpt_icon":0},{"id":"2448971701","title":"诺诚健华盘中异动 急速拉升5.19%报5.071港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2448971701","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448971701?lang=zh_cn&edition=full","pubTime":"2024-07-02 10:03","pubTimestamp":1719885824,"startTime":"0","endTime":"0","summary":"2024年07月02日早盘10时03分，诺诚健华股票出现异动，股价大幅上涨5.19%。截至发稿，该股报5.071港元/股，成交量118.4万股，换手率0.08%，振幅5.19%。资金方面，该股资金流入399.502万港元，流出112.895万港元。诺诚健华股票所在的生物技术行业中，整体涨幅为0.09%。其相关个股中，歌礼制药-B、金斯瑞生物科技、诺诚健华涨幅较大，振幅较大的相关个股有来凯医药-B、帝王国际投资、歌礼制药-B，振幅分别为11.13%、9.38%、8.75%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240702100344aef77bff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240702100344aef77bff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","BK1574","BK1161","688428"],"gpt_icon":0},{"id":"2448971514","title":"“体重管理年”提振“减肥降糖药”概念！港股创新药ETF(159567)跟踪指数趋势上行，金斯瑞生物科技、信达生物、诺诚健华领涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2448971514","media":"有连云","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448971514?lang=zh_cn&edition=full","pubTime":"2024-07-02 10:01","pubTimestamp":1719885719,"startTime":"0","endTime":"0","summary":"2024年7月2日，港股创新药板块开盘走强。盘面上，金斯瑞生物科技领涨，信达生物、诺诚健华跟涨，港股创新药ETF市场热度较高，过去5个交易日日均成交额5505万元。首创证券表示，2024年6月26日，国家卫生健康委等16个部门联合制定并发布《“体重管理年”活动实施方案》。本次活动方案有助于提升社会大众对于减重在健康管理中重要性的认知，减重药物需求有望进入快速增长阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024070210020195630781&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024070210020195630781&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2328871848.SGD","688428","LU1969619763.USD","BK1576","BK1589","01548","01801","BK1583","BK1141","09969","BK1574","BK1161"],"gpt_icon":0},{"id":"2448979334","title":"化学制药行业盘中拉升，诺诚健华-U涨4.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2448979334","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448979334?lang=zh_cn&edition=full","pubTime":"2024-07-02 09:35","pubTimestamp":1719884158,"startTime":"0","endTime":"0","summary":"07月02日，化学制药行业盘中拉升，截至09点35分，化学制药行业整体指数上涨0.52%，报9052.730点。从个股上来看，该行业的成分股中，诺诚健华-U涨4.02%，海南海药、能特科技、博瑞医药涨幅居前。从资金上来看，截止发稿，化学制药行业主力净流入为-4517.09万，其中博瑞医药受到资金热捧，主力净流入533.65万；拉长时间线来看，该板块近20日主力资金净流入-53.60亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240702093558941f2e00&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240702093558941f2e00&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688428"],"gpt_icon":0},{"id":"2446557760","title":"诺诚健华(09969)授出279万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2446557760","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446557760?lang=zh_cn&edition=full","pubTime":"2024-06-28 18:40","pubTimestamp":1719571226,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华(09969)公布，于2024年6月28日，公司根据2023年股权激励计划授予八名承授人279万份受限制股份单位，相当于公司于本公告日期已发行股份总数的约0.16%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1142632.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","688428","09969","BK1574","BK0239"],"gpt_icon":0},{"id":"2446054738","title":"诺诚健华-U创1月新高 全球医药市场数字化转型提速","url":"https://stock-news.laohu8.com/highlight/detail?id=2446054738","media":"智选洞察","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446054738?lang=zh_cn&edition=full","pubTime":"2024-06-28 13:20","pubTimestamp":1719552000,"startTime":"0","endTime":"0","summary":"06月28日，诺诚健华-U股价大幅上涨，截至13点20分，诺诚健华-U上涨5.08%，报8.27元/股，创近1月新高，成交4470万元，换手率2.15%。目前Veeva研发云在全球范围内已被超过1000家生命科学企业采用，用于革新药企研发流程和加速数字化转型。主营业务及业绩诺诚健华-U公司主营业务为诺诚健华医药有限公司是一家主要从事生物医药的研发、生产和商业化的中国公司。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240628132158aef70d3e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240628132158aef70d3e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159938","688428","BK0239"],"gpt_icon":0},{"id":"2446385547","title":"诺诚健华-U上涨5.08%，报8.27元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2446385547","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446385547?lang=zh_cn&edition=full","pubTime":"2024-06-28 13:19","pubTimestamp":1719551981,"startTime":"0","endTime":"0","summary":"6月28日，诺诚健华-U盘中上涨5.08%，截至13:19，报8.27元/股，成交4460.04万元，换手率2.14%，总市值145.77亿元。截至3月31日，诺诚健华-U股东户数1.77万，人均流通股9.94万股。2024年1月-3月，诺诚健华-U实现营业收入1.66亿元，同比减少12.44%；归属净利润-1.42亿元，同比减少1047.82%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062813223895e10b0f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062813223895e10b0f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","BK1161","688428","BK1574"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2022-09-21","address":"OgierGlobal(Cayman)Limited,89NexusWay,CamanaBay,GrandCayman,KY1-9009,CaymanIslands","stockEarnings":[{"period":"1week","weight":0.0936},{"period":"1month","weight":0.2738},{"period":"3month","weight":0.185},{"period":"6month","weight":-0.0508},{"period":"1year","weight":-0.182},{"period":"ytd","weight":-0.187}],"companyName":"诺诚健华医药有限公司","boardCode":"AI0027","perCapita":"--","boardName":"医药制造业","registeredCapital":"0万元","compareEarnings":[{"period":"1week","weight":0.008},{"period":"1month","weight":-0.0176},{"period":"3month","weight":-0.0362},{"period":"6month","weight":0.0461},{"period":"1year","weight":-0.0735},{"period":"ytd","weight":-0.0041}],"survey":"　　诺诚健华医药有限公司的主营业务为创新药的研发、生产及商业化。主要产品为奥布替尼、ICP-192、ICP-723、ICP-332、ICP-189、ICP-490、Tafasitamab、ICP-105、ICP-033、ICP-488、ICP-248、ICP-B03、ICP-915、ICP-B02等。公司获得奖项为中国技术创业协会科技创新贡献奖、北京市“专精特新”中小企业、中国新经济企业500强等。","serverTime":1721284804155,"listedPrice":11.03,"stockholders":"0人","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(688428)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,688428,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(688428)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}